CoWatch Maker Announces 'Best Value Fitness Tracker'
SAN JOSE, Calif., May 26, 2017 /PRNewswire/ -- iMCO Technology announces a fitness tracker that offers quality and features of expensive products on the market, but only for a fraction of the brand name prices. The tracker also has either more features or better performance than similarly priced competitions.
The fitness tracker, iMCO CoBand K4, retails for $32.95 and is currently on sale for $19.95 at iMCO online store (shop.imcotechnology.com). At this price, the tracker offers an array of features:
Fitness tracking: steps, distance, calories
Health tracking: heart rate, sleep quality
Large OLED screen to read scrolling text message
Horizontal or vertical display
Variety of phone notifications via Bluetooth
Raise arm to turn on display
choice of six colors
IP65 water resistance rating
Long battery life (up to five days per charge)
Free iOS and Android apps
About iMCO Technology
iMCO focuses on innovative, fashionable products designed and developed in an effort to perfect the everyday mobile life. iMCO Watch, formerly known as CoWatch, is the first smart watch in the world that integrates with Amazon Alexa voice service. By offering smart wearables, including fitness bands and smart watches, as well as mobile accessories such as power bank, car charger, and Bluetooth wireless speakers, iMCO is fully committed and well positioned to "perfect your mobile life."
The 31st Canadian Cancer Society (CCS) Daffodil Ball, which took place this evening at Windsor Station in Montreal, raised $1,474,785 to fund innovative research projects and essential support programs for people living with cancer. The largest...
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....
RevolKa Ltd. (Norio Hamamatsu, President & CEO), a venture-backed biotech company providing a game-changing protein engineering technology platform and La Jolla Institute for Immunology (LJI) (Erica Saphire, President & CEO) agreed to start a...
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...
